June 2, 2021 07:47 AM EDT
R&D
FDA+

Af­ter tak­ing a look at new da­ta, reg­u­la­tors put J&J's BC­MA/CD3 bis­pe­cif­ic on a 'break­through' track

Nicole DeFeudis

Editor

Af­ter of­fer­ing a peek at the up­dat­ed da­ta it’s bring­ing to AS­CO next week, J&J is mov­ing in­to the fast lane …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

No­var­tis, Ab­b­Vie and PhRMA se­cure 340B court win in West Vir­ginia

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

A service from the Financial Times